Table 3.
Variable | Tertile 1 (n=104) (<0.92 mIU/L) median (IQR): 0.70 (0.52–0.79) | Tertile 2 (n=108) (0.92–1.62 mIU/L) median (IQR): 1.19 (1.07–1.40) | Tertile 3 (n=108) (N1.62 mIU/L) median (IQR): 2.37 (1.96–3.87) | p-value |
---|---|---|---|---|
Sex | ||||
Male | 49 | 74 | 69 | <0.01 |
Female | 55 | 34 | 39 | |
History of MI/HF | ||||
Yes | 36 | 36 | 42 | 0.67 |
No | 68 | 72 | 66 | |
ASA | ||||
Yes | 27 | 28 | 21 | 0.43 |
No | 77 | 80 | 87 | |
Heparin treatment | ||||
23 | 21 | 26 | 0.68 | |
81 | 87 | 82 | ||
1996 MI diagnosis | ||||
Yes | 12 | 17 | 25 | 0.07 |
No | 92 | 91 | 83 | |
Time from onset for earliest PAPP-A measurement | ||||
Median hours (IQR) | 4 (2–9) | 4 (2–8) | 4 (2–8) | 0.42 |
Earliest cTnI | ||||
Median μg/L (IQR) | 0.01 (0.00–0.03) | 0.01 (0.00–0.04) | 0.01 (0.00–0.06) | 0.40 |
Peak cTnI | ||||
Median μg/L (IQR) | 0.02 (0.01–0.12) | 0.02 (0.01–0.14) | 0.03 (0.01–0.41) | 0.24 |
Earliest hs-cTnI | ||||
Median ng/L (IQR) | 8.11 (4.86–41.4) | 9.64 (4.34–38.3) | 19.5 (6.04–87.1) | 0.04 |